These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 33188959)

  • 1. Is there a role for bisphosphonates in vascular calcification in chronic kidney disease?
    Hildebrand S; Cunningham J
    Bone; 2021 Jan; 142():115751. PubMed ID: 33188959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption.
    Price PA; Faus SA; Williamson MK
    Arterioscler Thromb Vasc Biol; 2001 May; 21(5):817-24. PubMed ID: 11348880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue.
    Toussaint ND; Elder GJ; Kerr PG
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):221-33. PubMed ID: 18987295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder.
    Neven E; Vervaet B; Brand K; Gottwald-Hostalek U; Opdebeeck B; De Maré A; Verhulst A; Lalau JD; Kamel S; De Broe ME; D'Haese PC
    Kidney Int; 2018 Jul; 94(1):102-113. PubMed ID: 29716795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The kidney and bisphosphonates.
    Miller PD
    Bone; 2011 Jul; 49(1):77-81. PubMed ID: 21232648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial.
    Toussaint ND; Lau KK; Strauss BJ; Polkinghorne KR; Kerr PG
    Am J Kidney Dis; 2010 Jul; 56(1):57-68. PubMed ID: 20347511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Effects of Bisphosphonates on Ectopic Skin and Vascular Soft Tissue Mineralization versus Bone Microarchitecture in a Mouse Model of Generalized Arterial Calcification of Infancy.
    Li Q; Kingman J; Sundberg JP; Levine MA; Uitto J
    J Invest Dermatol; 2016 Jan; 136(1):275-283. PubMed ID: 26763447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates: preclinical aspects and use in osteoporosis.
    Fleisch HA
    Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of Bisphosphonates in Patients with Chronic Kidney Disease.
    Ott SM
    Semin Dial; 2015; 28(4):363-9. PubMed ID: 25940768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New bisphosphonates in the treatment of bone diseases.
    Gatti D; Adami S
    Drugs Aging; 1999 Oct; 15(4):285-96. PubMed ID: 10582775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series.
    Amerling R; Harbord NB; Pullman J; Feinfeld DA
    Blood Purif; 2010; 29(3):293-9. PubMed ID: 20090316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
    Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular calcification in chronic kidney disease: role of disordered mineral metabolism.
    Palit S; Kendrick J
    Curr Pharm Des; 2014; 20(37):5829-33. PubMed ID: 24533939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low bone turnover is associated with plain X-ray vascular calcification in predialysis patients.
    Neto R; Pereira L; Magalhães J; Quelhas-Santos J; Frazão J
    PLoS One; 2021; 16(10):e0258284. PubMed ID: 34644326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates: from the laboratory to the clinic and back again.
    Russell RG; Rogers MJ
    Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
    Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M
    J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.